Home › NDC Lookup › Ingredients › Dimenhydrinate › 00904-6772-12
⚪image loading
(from DailyMed)

Dimenhydrinate 50 mg Tablet, 12-count — NDC 0904-6772-12 (Billing 00904-6772-12)

by Major Pharmaceuticals · 1 BLISTER PACK in 1 CARTON / 12 TABLET in 1 BLISTER PACK

This is a package of 12 tablets of Dimenhydrinate 50 mg Tablet from Major Pharmaceuticals, marketed since Feb 2019 and currently FDA-listed, this package's marketing is listed to end Aug 2028; retail pharmacies pay about $0.0575 per tablet (NADAC). It is this product's only package size.

NDC 00904-6772-12
🏷️ FDA NDC (as labeled) 0904-6772-12 billing pads the labeler segment with a zero
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0904-6772-12
Product NDC 0904-6772
11-digit billing NDC 00904677212
NCPDP billing unit EA — each (per item)
RxCUI 198603
UNII JB937PER5C
UPC 0309046772125
Application # M009
SPL Set ID 78d22836-a442-7c0c-e053-2991aa0a62f3
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2019-02-14
Marketing end 2028-08-31
Route ORAL
Dosage form TABLET
Substance DIMENHYDRINATE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 50200030000310
GPI class Driminate
GCN Seq No 004720
GCN 18231
HICL code 004603
Ingredient (HICL) Dimenhydrinate
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H6
Therapeutic class — intermediate (HIC2) Drugs Acting Principally On The Midbrain
HIC3 code H6J
Therapeutic class — specific (HIC3) Antiemetic/Antivertigo Agents
AHFS code 04:04.00.00
AHFS class First Generation Antihistamines
FDB label name DRIMINATE 50 MG TABLET
FDB brand name Driminate
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 004720
  • GCN: 18231
  • GPI-14 (Medi-Span): 50200030000310
  • HICL (First Databank): 004603
  • AHFS class code: 04:04.00.00
  • RxCUI (RxNorm): 198603
Why two NDCs? The FDA registers this code as 0904-6772-12 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00904-6772-12. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Aminoalkyl ethers class.

Drug family (ATC) Aminoalkyl ethers
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name DRIMINATE 50 MG TABLET Ingredient Dimenhydrinate
📖 What it is MedlinePlus · NLM

Dimenhydrinate is used to prevent and treatmotion sickness. Dimenhydrinate is in a class of medications called antihistamines. It works by preventing problems with body balance.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It prevents and treats the nausea, vomiting and dizziness of motion sickness. You'll see it in products like Dramamine and Gravol, and as an injection used in medical settings.
  • To prevent motion sickness, take your first dose about 30 to 60 minutes before you start traveling. After that, follow the repeat timing and daily limit on your product's label. Ch...
  • Quite possibly. Drowsiness is the most common side effect. Be careful driving or using machinery, and skip alcohol.
  • Tell me what else you take. Sedatives, tranquilizers and other sedating drugs can add to drowsiness. It can also hide warning signs of ear damage from certain antibiotics.
📖 Read our full Dimenhydrinate guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.058 $0.69 / 12 tablets
Medicaid paysCMS SDUD · 12 mo $0.7239 $8.69 / 12 tablets
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2021 Aug 2022 Jan 2026 Sep 2026 $0.072 $0.036
▼ Down 1% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00904-6772-12 You're viewing this Main listing 1 BLISTER PACK in 1 CARTON / 12 TABLET in 1 BLISTER PACK 2019-02-14 Aug 31, 2028 Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Dimenhydrinate 50 mg 70000-0404-01 LEADER/ 12 tablets $0.054 — Availability likely save 6%
Driminate 50 mg 00904-2051-59 Major 100 tablets $0.058 — Availability likely —
Dimenhydrinate 50 mgthis 00904-6772-12 Major 12 tablets $0.058 — Availability likely —
Motion Sickness Relief 50 mg 46122-0536-53 Amerisource 12 tablets $0.058 — Availability likely —
Motion Sickness Relief 50 mg 70000-0749-01 Cardinal 12 tablets $0.058 — Availability likely —
Motion Sickness 50 mg 70677-1087-01 Strategic 12 tablets $0.058 — Availability likely —
Motion Sickness Relief 50 mg 83324-0032-12 Chain 12 tablets $0.058 — Availability likely —
Motion Sickness Relief 50 mg 00363-1980-08 Walgreen 24 tablets — — FDA listed —
Gravol 50 mg 10237-0941-10 Church 10 tablets — — FDA listed —
Motion Sickness 50 mg 11673-0198-02 Target 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 11673-0354-24 TARGET 24 tablets — — FDA listed —
Motion Sickness Relief 50 mg 11822-0198-02 Rite 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 36800-0930-12 Topco 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 49035-0981-12 Wal-Mart 100 tablets — — FDA listed —
Motion Sickness 50 mg 50804-0198-02 Geiss, 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 50844-0199-02 L.N.K. 12 tablets — — FDA listed —
Motion Sickness 50 mg 59779-0198-02 CVS 12 tablets — — FDA listed —
Dramamine Original Formula 50 mg 63029-0901-01 Medtech 36 tablets — — FDA listed —
Motion Sickness Relief 50 mg 63941-0198-02 Valu 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 67091-0118-12 WinCo 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 69168-0408-86 Allegiant 12 tablets — — FDA listed —
Dimenhydrinate 50 mg 69842-0206-12 CVS 12 tablets — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2019
On the market since
Feb 2019
📍
2026
Currently FDA-listed
7 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII M28OL1HH48
    Croscarmellose sodium is a plant-based substance derived from cellulose. It acts as a disintegrant, helping tablets and capsules break down quickly in the digestive system so the medicine can be absorbed.
  • UNII O7TSZ97GEP
    A mineral compound that serves as a filler and binding agent in tablets and capsules. It adds bulk to the medicine and helps hold ingredients together during manufacturing.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.

4 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statescroscarmellose sodium, dicalcium phosphate, magnesium stearate, microcrystalline cellulose

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerMajor Pharmaceuticals
FDA applicationM009 (OTC MONOGRAPH DRUG)
Labeler code00904
First marketedFeb 2019
Product typeHuman Otc Drug
Portfolio630 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🆘 Overdosage 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Ask a Doctor Before Use If 📄 Ask a Doctor or Pharmacist Before Use If 📄 When Using This Product 🤰 If Pregnant or Breast-Feeding 📄 Keep Out of Reach of Children 📄 Other Information 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 15 words ▾

Uses for the prevention and treatment of nausea, vomiting, or dizziness associated with motion sickness

⏱️ Dosage and Administration 111 words ▾

Directions ■ to prevent motion sickness, the rst dose should be taken one-half to one hour before starting activity ■ adults and children 12 years of age and over: 1 to 2 tablets every 4-6 hours; not to exceed 8 tablets in 24 hours, or as directed by a doctor ■ children 6 to under 12 years of age : 1/2 to 1 tablet every 6-8 hours; not to exceed 3 tablets in 24 hours, or as directed by a doctor ■ children 2 to under 6 years of age : 1/2 tablet every 6-8 hours; not to exceed 1 1/2 tablets in 24 hours, or as directed by a doctor

⚠️ Warnings 123 words ▾

Do not give to children under 2 years of age unless directed by a doctor Ask a doctor before use if you have ■ glaucoma ■ a breathing problem such as emphysema or chronic bronchitis ■ trouble urinating due to an enlarged prostate gland Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers When using this product ■ marked drowsiness may occur ■ avoid alcoholic drinks ■ alcohol, sedatives, and tranquilizers may increase drowsiness ■ use caution when driving a motor vehicle or operating machinery If pregnant or breast-feeding, ask a health professional before use. .

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center (1-800-222-1222) right away.

🆘 Overdosage 16 words ▾

In case of overdose, get medical help or contact a Poison Control Center (1-800-222-1222) right away.

🧪 Active Ingredient 10 words ▾

Drug Facts Active ingredient (in each tablet) Dimenhydrinate 50 mg

🧪 Inactive Ingredients 8 words ▾

croscarmellose sodium, dicalcium phosphate, magnesium stearate, microcrystalline cellulose

🎯 Purpose 2 words ▾

Purpose Antiemetic

📄 Ask a Doctor Before Use If 29 words ▾

Ask a doctor before use if you have ■ glaucoma ■ a breathing problem such as emphysema or chronic bronchitis ■ trouble urinating due to an enlarged prostate gland

📄 Ask a Doctor or Pharmacist Before Use If 14 words ▾

Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers

📄 When Using This Product 32 words ▾

When using this product ■ marked drowsiness may occur ■ avoid alcoholic drinks ■ alcohol, sedatives, and tranquilizers may increase drowsiness ■ use caution when driving a motor vehicle or operating machinery

🤰 If Pregnant or Breast-Feeding 11 words ▾

If pregnant or breast-feeding, ask a health professional before use. .

📄 Keep Out of Reach of Children 6 words ▾

Keep out of reach of children.

📄 Other Information 53 words ▾

Other information ■ each tablet contains: calcium 30 mg ■ store in a dry place at 15° – 30°C (59° – 86°F) ■ protect from moisture ■ see end -ap for expiration date and lot number ■ TAMPER EVIDENT: DO NOT USE IF OUTER PACKAGE IS OPENED OR BLISTER IS TORN OR BROKEN

📄 Questions or Comments 4 words ▾

Questions or comments? 1-800-231-4670

📄 Package Label / Principal Display Panel 36 words ▾

MAJOR ® NDC 0904-6772-12 Compare to the Active Ingredient in DRAMAMINE ® Original Formula* Driminate TM Dimenhydrinate USP, Antiemetic For Nausea, Dizziness and Vomiting from Motion Sickness 12 Tablets 50mg Each Use as Directed Major Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
976
Units reimbursed last 4 qtrs
11.7K
Gross reimbursed last 4 qtrs
$8.5K
Avg / prescription
$8.69
Avg / unit
$0.7239
Latest quarter Q1 2026
109Rx
Medicaid pays / ea
$0.7239
gross reimbursed
vs
NADAC / ea
$0.0575
acquisition cost
=
Spread
+$0.6664
+1159% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
100% MCO
Fee-for-service · 0 Rx Managed care · 976 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: no data reported NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: 11,720 units · 106 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
106106
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Georgia 106 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2025 (Q1-Q4)

Medicare Part D (outpatient prescription) spending for Dimenhydrinate — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Dimenhydrinate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Total Part D spend
$4K
Claims incl. refills
15
Beneficiaries
—
Spend / beneficiary
—
Spend / claim
$269.22
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 00904-6767-20 · Major 00904-6773-61 · Major →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.